About US
Contact us
-
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?The old adage “better late than never” may seem tired, but it could be apropos for Pfizer’s newly FDA-approved PARP inhibitor, Talzenna. Pfizer picked up the drug in its $14 billion acquisition of Med2018/10/18
-
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digitalMerck & Co. is joining the chief digital officer parade. The pharma giant has poached Jim Scholefield from Nike to head up its global IT and digital strategy, becoming the latest Big Pharma to put2018/10/18
-
US FDA grants ODD to Lynparza for treatment of pancreatic cancerThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Lynparza(olaparib) to be used for the treatment of pancreatic cancer. Pancreatic cancer is a rare and life-thre2018/10/17
-
Immugenyx and Janssen to develop SLE model for drug developmentImmugenyx has signed a collaboration agreement with Janssen Research & Development to develop an in-vivo platform that will aid in treating systemic lupus erythematosus (SLE). Under the agreement2018/10/17
-
Teva's patent failure gives long-acting Copaxone generics free reinTeva's strategy for padding its Copaxone franchise even in the face of generic competition just took a major hit. The company lost its bid to defend the long-acting, 40mg version of the multiple scl2018/10/16
-
Neopharma snatches Dr. Reddy's API business as it continues global expansionJust weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business to the Middle2018/10/16
-
Is Bayer's first sell-off here? Animal health may be up for grabs as Monsanto weighs on pharmaWill Bayer heed the advice from investors and analysts and split up the conglomerate? New clues suggest it just might. The German company is weighing a sale of its animal health business as part of a2018/10/15
-
Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's banAfter Zhejiang Huahai Pharmaceutical’s tainted valsartan API triggered a global recall, the FDA slapped an import ban on the drugmaker. But the agency made a confusing mistake in announcing the move—a2018/10/15
-
UCLH initiates new trial for Alzheimer’s treatment in UKThe NIHR University College London Hospitals (UCLH) Clinical Research Facility in the UK has initiated a clinical trial, DESPIAD, to assess a new treatment called miridesap for Alzheimer’s disease. S2018/10/12
-
Ionis partners with Roche to advance new antisense drugIonis Pharmaceuticals has entered a deal worth up to $760m with Roche for further development of its antisense drug, IONIS-FB-L, to treat complement-mediated diseases. IONIS-FB-L is designed using Io2018/10/12